glp 1 hers Novo Nordisk Signs Deal with Hims & Hims & Hers Weight Loss
Description
The FDA's decision to grant orforglipron a Commissioner's National Priority Review Voucher further accelerated the regulatory timeline, potentially compressing the standard 10-12 month review period to as little as 1-2 months
Access to GLP-1s is only available to people with a BMI of 30 or higher, or 27 and higher with a weight-related health condition like high blood pressure, high cholesterol, or type 2 diabetes
Cohen, can lead to sustainable weight loss and enhance overall well-being
The high price of GLP-1 drugs could be substantially reduced in the future once they come off patent thereby allowing for the introduction of biosimilars
Both medications may improve cardiovascular health by reducing blood pressure, cholesterol, and inflammation
approval for chronic weight management
